From the *Division of Transplant Surgery, University Hospital “La Fe,” Valencia, Spain; †Division of Nephrology, University Hospital, Salamanca, Spain; and ‡Division of Pathology, University Hospital “La Fe,” Valencia, Spain.
Received July 30, 2010, and accepted for publication, after revision, November 13, 2010.
A CTA transplant program was approved at our institution by the Institutional Review Board and by the Spanish Organización Nacional de Transplantes (ONT).
There are no sources of support that require acknowledgment. The authors have no financial or personal relationships with other people or organizations that could influence (bias) this work inappropriately. The authors have no financial interest in any of the drugs mentioned in this work. Alemtuzumab, tacrolimus, sirolimus, and mycophenolate mofetil were used off-label to prevent and treat rejection of hand allografts.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.annalsplasticsurgery.com).
Reprints: Luis Landin, MD, Clinica Cavadas, Paseo de Facultades 1, bajo 8, 46021 Valencia, Spain. E-mail: [email protected].
